Israel Biotech Fund I, L.P. 的 Form 4 申報
Ayala Pharmaceuticals, Inc.（ADXS），2023/10/31 申報
- 申報編號
- 0001178913-23-003462
- 申報時間
- 2023/10/31 07:08 ET
- 交易日
- 2023/10/18
- 申報延遲
- 13 天遲報
- 10b5-1 計畫
- 沒有勾選
這份申報列了 2 筆非衍生性交易。交易後 13 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Israel Biotech Fund I, L.P.CIK 0001652458 | 持股 10% 以上大股東 |
| Israel Biotech Fund II, L.P.CIK 0001782947 | 持股 10% 以上大股東 |
| I.B.F. Management Ltd.CIK 0001994849 | 持股 10% 以上大股東 |
| Israel Biotech Fund GP Partners, L.P.CIK 0001994922 | 持股 10% 以上大股東 |
| Israel Biotech Fund GP Partners II, L.P.CIK 0001994923 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
As more fully described in a Schedule 13D/A filed by the Reporting Persons on October 31, 2023 (the "Schedule 13D/A"), on October 18, 2023, the Issuer issued to Israel Biotech Fund I, L.P. ("IBF 1") and IBF II Israel Biotech Fund II, L.P. ("IBF 2") 338,693 shares of Common Stock and 338,693 shares of Common Stock, respectively (collectively, the "Biosight Consideration Shares"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated July 26, 2023, by and among the Issuer, Advaxis Israel Ltd. and Biosight Ltd. (the "Biosight Merger").
表 I 有 2 筆交易的價格引用這則附註。
- F2
As more fully described in the Schedule 13D/A, (i) in connection with the Biosight Merger and pursuant to a Side Letter Agreement for Conversion, dated September 15, 2023 (the "Side Letter Agreement"), by and between the Issuer, IBF I, IBF II and certain other investors, the Issuer is also in the process of issuing to IBF I and IBF II 320,615 shares of Common Stock and 320,615 shares of Common Stock, respectively (collectively, the "SAFE Initial Shares"), and (ii) subject to the terms and conditions of the Side Letter Agreement, each of IBF I and IBF II has the right to invest additional $504,000 in the Issuer for a purchase price that is presently undeterminable (collectively, the "SAFE Additional Shares").
表 I 有 2 筆交易的價格引用這則附註。